I am an academic physician-scientist (MD, PhD), entrepreneur, and MBA with expertise in nephrology, purinergic signaling, obesity, cardiometabolic disease, and translational medicine. I founded ePurines to develop first-in-class therapeutics targeting P2Y2 receptors for obesity, metabolic syndrome, chronic kidney disease, and related disorders. My work integrates mechanistic biology, target identification, biomarker discovery, and AI-enabled approaches to cardiometabolic risk prediction and patient stratification. I help industry identify innovative therapeutic opportunities, evaluate emerging targets, de-risk early-stage programs, and translate academic discoveries into commercially viable drug development assets, strategic partnerships, and licensing opportunities.